Tempest Therapeutics, Inc. (TPST) - Form 8-K Summary
Business Context and Reporting Period
Tempest Therapeutics, Inc., a Delaware corporation headquartered in Brisbane, California, filed this Current Report on Form 8-K on March 30, 2026. The filing serves to announce the Company's financial results for the fiscal year ended December 31, 2025, and other business highlights.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notice of the results rather than a detailed financial statement. Specific metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the provided text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period within the body of the 8-K. It references the attached press release for the full scope of operational and financial changes for the year ended December 31, 2025.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, and unusual items are not explicitly detailed in the provided text. The Company directs investors to the press release (Exhibit 99.1) for these details. The filing includes standard disclaimers that the information furnished under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 30, 2026) for specific revenue, net loss, and cash position figures.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the business highlights.
- Confirm the status of any debt obligations or equity financing activities referenced in the full report.